Quarter Comparison
Revenue
Operating Income
Gross Margin
Net Margin
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 rnxt-ex99_1.htm EX-99.1 EX-99.1 RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth Increases 2026 Annual Revenue Guidance to a Range of $3.75M to $4.25M First Treatment Delivered with RenovoCath ® in P
EX-99.1 2 rnxt-ex99_1.htm EX-99.1 EX-99.1 RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth Increases 2026 Annual Revenue Guidance to a Range of $3.75M to $4.25M First Treatment Delivered with RenovoCath ® in Patient with Sarcoma in Clinical Setting, Marking Expansion of Device to Other Solid Tumors Phase III TIGeR-PaC Trial Reaches Full Enrollment; Completion of Trial Expected in First Half 2027 with Topline Data Readout Expected in Second Half 2027 Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif. – August 12, 2026 – RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a patented, FDA-cleared drug-delivery device, today announced its financial results f...
Source
Exhibit EX-99.1
0001193125-26-349157
Filed August 13, 2026 at 8:06 PM UTC. The figures above are from the audited statements, not from this release.